Collins T F, Ruggles D I, Holson J F, schumacher H, Gaylor D W, Kennedy G L
J Toxicol Environ Health. 1976 May;1(5):851-6. doi: 10.1080/15287397609529385.
Because of recent studies indicating possible embryolethality and teratogenicity of FD&C Red. No 2, and ad hoc committee was convened by the Food and Drug Administration to consider these questions. The committee suggested a collaborative study by three laboratories [Food and Drug Administration (FDA), Industrial Bio-Test Laboratories (IBT), and National Center for Toxicological Research (NCTR)] in which Red No. 2 was given at 200 mg/kg body weight, by gavage during days 0-19, 6-15, or 7-9 of gestation. FD*C Red No. 2 was also given at the same dose level via water bottle. Appropriate controls were utilized. FDA used Osborne-Mendel strain rats, IBT used Charles River strain also showed an increase in the same parameter for the same dose level and in addition showed a significant increase in the percentage of resorptions per litter. It was concluded that because of the inherent variation and the absence of an increase in abnormalities or other indications of embryotoxicity, there is reason to doubt that this effect is either biologically significant or reproducible.
由于近期研究表明FD&C红色素2号可能具有胚胎致死性和致畸性,食品药品监督管理局召集了一个特别委员会来审议这些问题。该委员会建议由三个实验室[食品药品监督管理局(FDA)、工业生物测试实验室(IBT)和国家毒理学研究中心(NCTR)]开展一项合作研究,在妊娠第0至19天、第6至15天或第7至9天,通过灌胃给予200毫克/千克体重的红色素2号。FD&C红色素2号也以相同剂量水平通过水瓶给予。采用了适当的对照。FDA使用奥斯本-孟德尔品系大鼠,IBT使用查尔斯河品系大鼠,在相同剂量水平下,同一参数也出现了增加,此外,每窝吸收百分比显著增加。得出的结论是,由于存在固有变异且异常情况或其他胚胎毒性迹象没有增加,因此有理由怀疑这种效应是否具有生物学意义或可重复性。